Elute, Inc.

Elute, Inc., based in Salt Lake City, UT, develops advanced technologies and products for restoring bone loss. BonVie+, combines bio-resorbable, osteoconductive materials designed to provide a stable scaffold when filled in bone voids, restores bone loss without drainage, and supports new growth. Engineered for optimal resorption and enhanced bone healing, our synthetic bone graft substitute is replaced by healthy bone in 3-12 months. EP Granules with Tobramycin, like BonVie+, but preloaded with tobramycin, enables controlled, locally targeted drug delivery over an unprecedented 8 weeks to address complex orthopedic infections. EP Granules with Tobramycin is an investigational device, limited to investigational use only. Our solutions are designed for ease of use, requiring no new training and integrating seamlessly into existing workflows. Committed to improving patient outcomes, Elute is advancing orthopedic treatment with smarter, innovative devices that overcome current limitations, empowering surgeons to deliver better care and improved patient outcomes.

• Employees 4
• Founded 2011
• Total Funding $1635000